Sample size formulae for the Bayesian continual reassessment method

Clinical Trials

Volumn 10, Issue 6, 2013, Pages 852-861

  Cheung, Ying Kuen ^a  

^a Mailman School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; BAYES THEOREM; BAYESIAN CONTINUAL REASSESSMENT METHOD; BAYESIAN LEARNING; CALCULATION; DOSE CALCULATION; HUMAN; LINEAR REGRESSION ANALYSIS; MATHEMATICAL ANALYSIS; NONPARAMETRIC TEST; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SAMPLE SIZE; SAMPLING;

BAYES THEOREM; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LINEAR MODELS; LOGISTIC MODELS; SAMPLE SIZE; STATISTICS AS TOPIC;

EID: 84889797030     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774513497294     Document Type: Article

References (21)

1. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: A practical design for phase I clinical studies in cancer. Biometrics. 1990 ; 46: 33-48
2. Durham SD, Flournoy N, Rosenberger WF. A random walk rule for phase I clinical trials. Biometrics. 1997 ; 53: 745-60
3. Cheung YK. Sequential implementation of stepwise procedures identifying the maximum tolerated dose. J Am Stat Assoc. 2007 ; 102: 1448-61
4. Cheung YK, Elkind MSV. Stochastic approximation with virtual observations for dose finding on discrete levels. Biometrika. 2010 ; 97: 109-21
5. Bartroff J, Lai TL. Approximate dynamic programming and its applications to the design of phase I cancer trials. Stat Sci. 2010 ; 25: 245-57
6. Lin Y, Shih WJ. Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics. 2001 ; 2: 203-15
7. Ivanova A. Escalation group and A+B designs for dose-finding trials. Stat Med. 2006 ; 21: 3668-78
8. Tighiouart M, Rogatko A. Number of patients per cohort and sample size considerations using dose escalation with overdose control. J Probab Stat. 2012 ; 2012:
9. Shen LZ, O'Quigley J. Consistency of continual reassessment method under model misspecification. Biometrika. 1996 ; 83: 395-405
10. Ahn C. An evaluation of phase I cancer clinical trial designs. Stat Med. 1998 ; 17: 1537-49
11. Cheung YK. Coherence principles in dose finding studies. Biometrika. 2005 ; 92: 863-73
12. Cheung YK, Chappell RJ. A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics. 2002 ; 58: 671-74
13. Lee SM, Cheung YK. Model calibration of the continual reassessment method. Clin Trials. 2009 ; 6: 227-38
14. Lee SM, Cheung YK. Calibration of prior variance in the Bayesian continual reassessment method. Stat Med. 2011 ; 30: 2081-89
15. Cheung YK Dose finding by the continual reassessment method. Boca Raton, FL: CRC Press/Taylor & Francis Group ; 2011:
16. O'Quigley J, Paoletti X, MacCario J. Non-parametric optimal design in dose finding studies. Biostatistics. 2002 ; 3: 51-56
17. O'Quigley J, Shen LZ. Continual reassessment method: A likelihood approach. Biometrics. 1996 ; 52: 673-84
18. Polley M-Y, Cheung YK. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests. Biometrics. 2008 ; 64: 232-41
19. Cheung YK. Commentary on 'Behavior of novel phase I cancer trial designs'. Clin Trials. 2013 ; 10: 86-87
20. Cheung YK, Chappell RJ. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000 ; 56: 1177-82
21. Shu J, O'Quigley J. Dose-escalation designs in oncology: ADEPT and the CRM. Stat Med. 2008 ; 27: 5345-53